

METRONIDAZOLE- metronidazole lotion
Fougera Pharmaceuticals, LLC

METRONIDAZOLE TOPICAL LOTION, 0.75%


FOR TOPICAL USE ONLY

Rx Only

(NOT FOR OPHTHALMIC USE)

DESCRIPTION

Metronidazole Topical Lotion, 0.75% contains metronidazole, USP, at a concentration of 7.5 mg per gram (0.75% w/w) in a lotion consisting of benzyl alcohol, carbomer 941, cyclomethicone, glycerin, glyceryl stearate, light mineral oil, PEG-100 stearate, polyethylene glycol 400, potassium sorbate, purified water, steareth-21, stearyl alcohol, and sodium hydroxide and/or lactic acid to adjust pH. Metronidazole is an imidazole and is classified therapeutically as an antiprotozoal and antibacterial agent. Chemically, metronidazole is 2-methyl-5-nitro-1*H*-imidazole-1-ethanol. The molecular formula is C₆H₉N₃O₃ and molecular weight is 171.16. Metronidazole is represented by the following structural formula:



CLINICAL PHARMACOLOGY

The mechanisms by which metronidazole acts in the treatment of rosacea are unknown, but appear to include an anti-inflammatory effect.

Pharmacokinetics

Absorption of metronidazole after topical application of metronidazole topical lotion is less complete and more prolonged than after oral administration. Detectable plasma levels were found in all subjects following the administration of a 1 gram dose of metronidazole topical lotion (containing 7.5 mg of metronidazole) applied every morning and evening for 4 days to the faces of 8 patients. The highest concentration (96 ng/mL) seen following the morning dose on Day 5 was approximately 80 times lower than the peak concentrations produced by a single 250 mg tablet of metronidazole. The mean (\pm SD) AUC₀₋₂₄ after twice daily administration was 962 \pm 373 ng.hr/mL.

INDICATIONS AND USAGE

Metronidazole topical lotion is indicated for topical application in the treatment of inflammatory papules and pustules of rosacea.

CLINICAL STUDIES

A controlled clinical study was conducted in 144 patients with moderate to severe rosacea, in which metronidazole topical lotion was compared with its vehicle. Applications were made twice daily for 12 weeks during which patients were instructed to avoid spicy foods, thermally hot foods and drinks, alcoholic beverages, and caffeine. Patients were also provided samples of a soapless cleansing lotion and, if requested, a moisturizer. Metronidazole topical lotion was significantly more effective than its vehicle in mean percent reduction of inflammatory lesions associated with rosacea and in the investigator's global assessment of improvement. The results of the mean percent reduction in inflammatory lesion counts from baseline after 12 weeks of treatment and the investigators' global assessment of improvement at week 12 are presented in the following table:

Efficacy Outcomes at Week 12						
Mean Percent Reduction in Inflammatory Lesion Counts from Baseline						
Metronidazole Topical Lotion N=65			Vehicle Lotion N=60			
55%			20%			
Investigators' Global Assessment of Improvement (percent change from baseline)						
	Worse	No Change	Minimal Improvement	Definite Improvement	Marked Improvement	Clear
Metronidazole Topical Lotion N=65	5%	12%	11%	32%	32%	8%
Vehicle Lotion N=60	15%	27%	23%	15%	20%	0%

The scale is based on the following definitions:

Worse:	Exacerbation of either erythema or quantitative assessment of papules and/or pustules.
No Change:	Condition remains the same.
Minimal Improvement:	Slight improvement in the quantitative assessment of papules and/or pustules, and/or slight improvement in erythema.
Definite Improvement:	More pronounced improvement in the quantitative assessment of papules and/or pustules, and/or more pronounced improvement in erythema.
Marked Improvement:	Obvious improvement in the quantitative assessment of papules and/or pustules, and/or obvious improvement in erythema.
Clear:	No papules or pustules and minimal residual or no erythema.

CONTRAINDICATIONS

Metronidazole topical lotion is contraindicated in individuals with a history of hypersensitivity to metronidazole or to other ingredients of the formulation.

PRECAUTIONS

General: Topical metronidazole formulations have been reported to cause tearing of the eyes. Therefore, contact with the eyes should be avoided. If a reaction suggesting local irritation occurs, patients should be directed to use the medication less frequently or discontinue use. Metronidazole is a nitroimidazole and should be used with care in patients with evidence or history of blood dyscrasia.

Information for Patients

Patients using metronidazole topical lotion should receive the following information and instructions:

1. This medication is to be used only as directed by the physician.
2. It is for external use only.
3. Avoid contact with the eyes.
4. Cleanse affected area(s) before applying this medication.
5. Patients should report any adverse reaction to their physician.

Drug Interactions

Oral metronidazole has been reported to potentiate the anticoagulant effect of warfarin and coumarin anticoagulants, resulting in a prolongation of prothrombin time. The effect of topical metronidazole on prothrombin time is not known.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats. Metronidazole has not been assessed for carcinogenic activity following topical administration. In several long term studies in mice, oral doses of approximately 200 mg/m²/day (approximately 20 times the exposure of a patient that received the estimated maximum human topical daily dose (assuming 100% bioavailability and following normalization of the data on the basis of the body surface area)) or greater were associated with increase incidences of lung tumors in male mice and lymphomas in female mice. In several long-term studies in rats, oral administration of metronidazole resulted in increased incidences of mammary and hepatic tumors in female rats and testicular tumors and pituitary adenomas in male rats at dosages of approximately 1600 mg/m²/day (approximately 170 times the exposure of a patient that received the estimated maximum human topical daily dose (assuming 100% bioavailability and following normalization of the data on the basis of the body surface area)) or greater. In another oral study, an increase of mammary tumors was observed in female rats that received approximately 160 mg/m²/day (approximately 17 times the exposure of a patient that received the estimated maximum human topical daily dose (assuming 100% bioavailability and the following normalization of the data on the basis of the body surface area)). Ultraviolet radiation- induced carcinogenesis was enhanced in albino mice by intraperitoneal injection of metronidazole at a dosage of 45 mg/m²/day, 5 days per week for 10 weeks, as indicated by a decreased latency period to the development of skin neoplasms. It is unclear how this level of exposure compares

to the clinical situation with respect to the concentration of the drug or metabolics in the skin. This study did not determine if metronidazole must be present during exposure to ultraviolet radiation in order to enhance tumor formation; metronidazole may promote tumor formation in cells that have previously been initiated by ultraviolet radiation.

Metronidazole exhibited mutagenic activity in several in vitro bacterial and mammalian assay systems. Intraperitoneal administration of metronidazole to mice resulted in a dosage-dependent increase in the incidence of chromosomal aberrations in peripheral lymphocytes was reported in patients with Crohn's disease who were treated with metronidazole for 1 to 24 months at a dosage of 200 to 1200 mg/day. However, similar results were not observed in another study, in which humans were treated for 8 months. In rats, oral metronidazole at a dosage of approximately 1800 mg/m²/day (approximately 200 times the exposure of a patient that received the estimated maximum human topical daily dose (assuming 100% bioavailability and following normalization of the data on the basis of body surface area)) induced inhibition of spermatogenesis and severe testicular degeneration.

Pregnancy: *Teratogenic Effects: Pregnancy Category B*

There are no adequate and well-controlled studies with the use of metronidazole topical lotion in pregnant women. Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity was observed after oral administration of metronidazole in rats or mice. However, because animal reproduction studies are not always predictive of human response and since oral metronidazole has been shown to be a carcinogen in some rodents, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

After oral administration, metronidazole is secreted in breast milk in concentrations similar to those found in the plasma. Even though blood levels are significantly lower with topically applied metronidazole than those achieved after oral administration of metronidazole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

In a controlled clinical trial, safety data from 141 patients who used metronidazole topical lotion (n=71), or the lotion vehicle (n=70), twice daily and experienced a local cutaneous adverse event which may or may not have been related to the treatments include: local allergic reaction, metronidazole topical lotion 2 (3%), lotion vehicle 0; contact dermatitis, metronidazole topical lotion 2 (3%), lotion vehicle 1 (1%); pruritus, metronidazole topical lotion 1 (1%), lotion vehicle 0; skin discomfort (burning and stinging), metronidazole topical lotion 1 (1%), lotion vehicle 2 (3%); erythema, metronidazole topical lotion 4 (6%), lotion vehicle 0; dry skin, metronidazole topical lotion 0, lotion vehicle 1 (1%); and worsening of rosacea, metronidazole topical lotion 1 (1%), and lotion vehicle 7 (10%).

The following additional adverse experiences have been reported with the topical use of

metronidazole: skin irritation, transient redness, metallic taste, tingling or numbness of extremities, and nausea.

DOSAGE AND ADMINISTRATION

Apply a thin layer to entire affected areas after washing. Use morning and evening or as directed by physician. Avoid application close to the eyes. Patients may use cosmetics after waiting for the metronidazole topical lotion to dry (not less than 5 minutes).

HOW SUPPLIED

Metronidazole Topical Lotion, 0.75% is supplied in the following size:

2 Fl Oz (59 mL) plastic bottle – NDC 0168-0383-60

Store at controlled room temperature, 20° to 25°C (68° to 77°F). Protect from freezing.

E. FOUGERA & CO.

A division of Fougera Pharmaceuticals Inc.

Melville, New York 11747

I2383C/IF2383C

R07/16

#124

PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 59 ML LABEL

NDC 0168-0383-60

Fougera

METRONIDAZOLE

TOPICAL LOTION, 0.75%

Rx Only

For Topical Use Only.

Not for Ophthalmic Use.

WARNING: Keep away from children.

2 Fl Oz (59 mL)

E. FOUGERA & CO.

A division of Fougera Pharmaceuticals Inc.

Melville, New York 11747



PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 59 ML CARTON

NDC 0168-0383-60

Fougera

METRONIDAZOLE

TOPICAL LOTION,

0.75%

Rx only

For Topical Use Only.

Not for Ophthalmic Use.

WARNING: Keep away


from children.

2Fl Oz (59 mL)

E. FOUGERA & CO.

A division of Fougera Pharmaceuticals Inc.

Melville, New York 11747



METRONIDAZOLE

metronidazole lotion

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0168-0383
Route of Administration	TOPICAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
METRONIDAZOLE (UNII: 140QMO216E) (METRONIDAZOLE - UNII:140QMO216E)	METRONIDAZOLE	7.5 mg in 1 mL

Inactive Ingredients

Ingredient Name	Strength
BENZYL ALCOHOL (UNII: LKG8494WBH)	
CARBOMER HOMOPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED) (UNII: F68VH75CJC)	
GLYCERIN (UNII: PDC6A3C0OX)	
GLYCERYL MONOSTEARATE (UNII: 230OU9XXE4)	
LIGHT MINERAL OIL (UNII: N6K5787QVP)	
PEG-100 MONOSTEARATE (UNII: YD01N1999R)	
POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)	
POTASSIUM SORBATE (UNII: 1VPU26JZZ4)	
WATER (UNII: 059QF0KO0R)	
STEARETH-21 (UNII: 53J3F32P58)	
STEARYL ALCOHOL (UNII: 2KR89I4H1Y)	
SODIUM HYDROXIDE (UNII: 55X04QC32I)	
LACTIC ACID, UNSPECIFIED FORM (UNII: 33X04XA5AT)	
CYCLOMETHICONE (UNII: NMQ347994Z)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0168-0383-60	59 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	05/24/2006	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA077197	05/24/2006	

Labeler - Fougera Pharmaceuticals, LLC (043838424)

Revised: 1/2026

Fougera Pharmaceuticals, LLC